Quick Takeaways:
- Zoetis has secured European Commission (EC) marketing authorization for Poulvac Procerta HVT-ND, a recombinant vector vaccine that protects chickens against Newcastle disease (ND) and Marek’s disease with a single dose. The vaccine can be administered in ovo or by subcutaneous injection at hatch
- The approval comes as Newcastle disease outbreaks continue across parts of Europe, including Germany, Spain, and Poland. Built on Zoetis’ HVT vector platform, the vaccine provides dual protection against ND and Marek’s disease. It also opens export opportunities for EU poultry producers to Southeast Asian markets, where the vaccine is already approved
- Already authorized in 35+ markets, Poulvac Procerta HVT-ND becomes the third EC-approved vaccine in the Procerta portfolio, joining Poulvac Procerta HVT-IBD and Poulvac Procerta HVT-IBD-ND. Zoetis expects the approval to strengthen flock health programs across Europe while expanding access to its poultry vaccine portfolio
Why It Matters?
Zoetis’ EC approval of Poulvac Procerta HVT-ND turns its single-dose, dual ND+Marek’s protection into a mainstream EU option, which should drive rapid adoption as producers shift from multi-vaccine schedules to a streamlined, in‑ovo or hatch-day protocol that better fits modern poultry operations. Given ongoing ND outbreaks in Germany, Spain, and Poland, the authorization is likely to accelerate uptake in affected countries and strengthen Zoetis’ position against competitors selling separate ND and Marek’s products.
Source: Businesswire
